Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25576364 | 1.00 | AGTR2 (0.61) | AGTR2AGTR1 | |
| SCHEMBL29958619 | 0.93 | AGTR2 (0.53) | AGTR2AGTR1 | |
| SCHEMBL29958648 | 0.93 | AGTR2 (0.51) | AGTR2AGTR1 | |
| SCHEMBL29958707 | 0.91 | AGTR2 (0.62) | AGTR2AGTR1 | |
| SCHEMBL29958531 | 0.91 | AGTR2 (0.62) | AGTR2AGTR1 | |
| SCHEMBL29958610 | 0.91 | AGTR2 (0.62) | AGTR2AGTR1 | |
| SCHEMBL23831165 | 0.91 | AGTR2 (0.71) | AGTR2AGTR1 | |
| SCHEMBL29958721 | 0.91 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL25576366 | 0.91 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL23831132 | 0.88 | AGTR2 (0.47) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159467-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2023-05-25 | — | — | US | claimed |
| EP-4121165-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | Vicore Pharma AB (SE) | 2023-01-25 | — | — | EP | claimed |
| US-20240182461-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| EP-4313953-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Vicore Pharma AB (SE) | 2024-02-07 | — | — | EP | disclosed |
| US-20230159467-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2023-05-25 | — | — | US | disclosed |
| EP-4121165-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | Vicore Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| CN-115605265-A | Novel compounds for the treatment and/or prevention of diseases, disorders or conditions associated with angiotensin ii | 维科尔药物公司（SE） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022200785-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182461-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | AGTR1, AGTR2, MSR1 | AGTR2 2/4885AGTR1 1/4885 |
| US-20230159467-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | AGTR2, AGTR1, AGT | AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.